EfficacyAzoles vs. placeboTwenty-ei

Efficacy
Azoles vs. placebo
Twenty-eight studies, comprising a total of 3044 patients,
compared the azoles bifonazole, clotrimazole, econazole,
ketoconazole, miconazole, oxiconazole, sertaconazole and tioconazole with placebo. The concentration of these drugs was 1% or 2% and they were used for 2–6 weeks. In terms of
mycological cure at the end of treatment, meta-analysis of data
from 26 RCTs estimated the pooled OR as 10Æ25 (95% CI
6Æ88–15Æ27), favouring azoles. There was a high degree of
heterogeneity (I 2 = 71%) among the studies selected for the
meta-analysis. Sensitivity analyses were carried out by pooling
the studies into subgroups based on the dermatomycosis
evaluated. When the heterogeneity remained high, a hypothet-
ical removal of the studies responsible for that heterogeneity
was performed. By the sensitivity analyses performed, the I 2
decreased, becoming low or moderate, and the OR value
remained statistically significant, favouring treatment with
azoles.

Hasil (Bahasa Indonesia) 1:

KhasiatAzoles vs placeboDua puluh delapan studi, terdiri dari total 3044 pasien,dibandingkan azoles bifonazole, clotrimazole, econazole,ketoconazole, miconazole, oxiconazole, sertaconazole dan tioconazole dengan plasebo. Konsentrasi obat ini adalah 1% atau 2% dan mereka digunakan untuk 2-6 minggu. Dari segijamur obat pada akhir pengobatan, meta-analisis datadari 26 RCTs diperkirakan OR terkumpul sebagai 10Æ25 (95% CI6Æ88-15Æ27), mendukung azoles. Ada tingkat tinggiheterogenitas (saya 2 = 71%) di antara studi dipilih untukmeta-analisis. Analisis sensitivitas dilaksanakan dengan penggabunganstudi ke subkumpulan berdasarkan dermatomycosisdievaluasi. Kapan heterogenitas tetap tinggi, hypothet-penghapusan iCal studi yang bertanggung jawab untuk heterogenitas itudilakukan. Oleh analisis sensitivitas dilakukan, saya 2menurun, menjadi rendah atau moderat, dan nilai ORtetap secara statistik signifikan, menguntungkan pengobatan denganazoles.